Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Non-Current Debt (2020 - 2026)

ADC Therapeutics has reported Non-Current Debt over the past 7 years, most recently at $111.0 million for Q1 2026.

  • Quarterly results put Non-Current Debt at $111.0 million for Q1 2026, down 2.42% from a year ago — trailing twelve months through Mar 2026 was $111.0 million (down 2.42% YoY), and the annual figure for FY2025 was $112.5 million, down 1.04%.
  • Non-Current Debt reached $111.0 million in Q1 2026 per ADCT's latest filing, down from $112.5 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $115.2 million in Q3 2025 and bottomed at $111.0 million in Q1 2026.
  • Median Non-Current Debt over the past 5 years was $113.7 million (2024), compared with a mean of $113.6 million.
  • The largest annual shift saw Non-Current Debt soared 32.15% in 2022 before it decreased 2.42% in 2026.
  • Over 5 years, Non-Current Debt stood at $115.2 million in 2022, then dropped by 2.15% to $112.7 million in 2023, then grew by 0.83% to $113.6 million in 2024, then fell by 1.04% to $112.5 million in 2025, then decreased by 1.25% to $111.0 million in 2026.
  • Business Quant data shows Non-Current Debt for ADCT at $111.0 million in Q1 2026, $112.5 million in Q4 2025, and $115.2 million in Q3 2025.